4LRH
|
queue
|
2023-12-07 09:12:50
|
4LRH
|
queue
|
2023-12-07 09:12:46
|
cfeaeb76a69975c
|
queue
|
2023-12-05 05:59:47
|
6f2b0d2ce7ee6ea
|
queue
|
2023-11-30 11:01:56
|
Liang LI
|
queue
|
2023-11-29 07:21:19
|
CACNA1g_Mutado
|
queue
|
2023-11-27 14:09:18
|
5xaj
|
queue
|
2023-11-26 22:59:55
|
test hf
|
queue
|
2023-11-22 16:27:05
|
HDP4
|
queue
|
2023-11-20 01:48:55
|
d22a3c07cfcc50b
|
queue
|
2023-11-18 08:03:16
|
327cef475c98355
|
queue
|
2023-11-18 08:03:08
|
U2301
|
queue
|
2023-11-17 09:25:16
|
TkADH
|
queue
|
2023-11-16 12:29:54
|
2e63d0ceb914aaf
|
queue
|
2023-11-16 12:29:24
|
40f0ba6a83e3ca3
|
queue
|
2023-11-13 03:36:01
|
fbfa058bba908ee
|
queue
|
2023-11-06 16:20:42
|
khjbjk [mutate: CA84A, VA50A, AA52A, VA93G]
|
queue
|
2023-11-06 16:18:46
|
BCSN1
|
queue
|
2023-11-06 10:06:55
|
Kuru Disease
|
queue
|
2023-11-02 19:41:54
|
3ae418504b848d3
|
queue
|
2023-11-02 16:18:10
|
eptinezumab
|
queue
|
2023-11-02 08:43:16
|
CTX_hydrophobicity
|
queue
|
2023-10-27 10:01:14
|
2a76b8eecc21e7e
|
queue
|
2023-10-26 03:06:44
|
P13-DYJ
|
queue
|
2023-10-24 01:59:18
|
P12-DYJ
|
queue
|
2023-10-24 01:58:37
|
P11-DYJ
|
queue
|
2023-10-24 01:55:53
|
SuBAL
|
queue
|
2023-10-20 11:06:28
|
SsBAL
|
queue
|
2023-10-20 11:05:52
|
PfBAL
|
queue
|
2023-10-20 11:05:11
|
AsBAL
|
queue
|
2023-10-20 11:04:37
|
PaBAL
|
queue
|
2023-10-20 11:03:27
|
No.5 0136
|
queue
|
2023-10-20 11:01:35
|
No.4 194
|
queue
|
2023-10-20 11:00:22
|
No.3 079
|
queue
|
2023-10-20 10:59:34
|
No.2 132
|
queue
|
2023-10-20 10:58:28
|
No.1 MCF
|
queue
|
2023-10-20 10:55:08
|
FDSYSFWNYVIFW
|
queue
|
2023-10-13 08:41:42
|
FGF-21
|
queue
|
2023-10-13 06:03:19
|
FGF-21
|
queue
|
2023-10-13 06:01:38
|
FGF-21 [mutate: LA98R] [mutate: FA73T]
|
queue
|
2023-10-13 05:56:20
|
5bf7b0be2ba35cb
|
queue
|
2023-10-13 02:40:14
|
a31e2d0a2debe76
|
queue
|
2023-10-13 02:40:09
|
some project name
|
queue
|
2023-10-12 02:26:24
|
some project name
|
queue
|
2023-10-12 01:49:26
|
82467bd4218c2bc
|
queue
|
2023-10-12 01:48:58
|